Abilify News and Research

RSS
Aripiprazole (marketed as Abilify, Abilify Discmelt) is an atypical antipsychotic medication approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.
UCLA-led study to evaluate treatment strategies for older adults with depression

UCLA-led study to evaluate treatment strategies for older adults with depression

EPFL scientists develop new method to cheaply produce chemical compounds

EPFL scientists develop new method to cheaply produce chemical compounds

Two-drug combination relieves depression in older adults

Two-drug combination relieves depression in older adults

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Lundbeck, Otsuka reach agreement to develop and commercialize Lu AE58054

Lundbeck, Otsuka reach agreement to develop and commercialize Lu AE58054

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

First-ever comprehensive study of species origins of nature-derived drugs

First-ever comprehensive study of species origins of nature-derived drugs

CDR recommends reimbursement for schizophrenia drug, ABILIFY

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia